Brio Consultants LLC Sells 434 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Brio Consultants LLC lowered its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 20.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,739 shares of the medical research company’s stock after selling 434 shares during the period. Brio Consultants LLC’s holdings in Bio-Rad Laboratories were worth $571,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Van ECK Associates Corp grew its stake in shares of Bio-Rad Laboratories by 97.8% during the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock valued at $436,861,000 after buying an additional 644,530 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Bio-Rad Laboratories by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock worth $147,583,000 after acquiring an additional 4,260 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Bio-Rad Laboratories by 3.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock worth $84,571,000 after purchasing an additional 9,584 shares during the period. Point72 Asset Management L.P. bought a new stake in Bio-Rad Laboratories in the third quarter valued at approximately $83,681,000. Finally, Mawer Investment Management Ltd. boosted its stake in shares of Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $361.79 on Friday. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99. The company has a 50-day simple moving average of $340.27 and a two-hundred day simple moving average of $335.04. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. The company had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.33 earnings per share. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BIO shares. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Citigroup raised their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.